Encompass Health (EHC) - 2024 Q2 - Quarterly Results

Executive Summary & Highlights Q2 2024 Performance Overview Encompass Health reported strong Q2 2024 results with significant revenue and Adjusted EBITDA growth, driven by increased discharges and net revenue per discharge Q2 2024 Financial Metrics | Metric | Q2 2024 | Q2 2023 | Change | Percent Change | | :------------------------------------------------------------------- | :-------- | :-------- | :-------- | :------------- | | Net operating revenue (In Millions) | $1,301.2 | $1,187.1 | $114.1 | 9.6 % | | Income from continuing operations attributable to Encompass Health per diluted share | 1.13 | 0.91 | 0.22 | 24.2 % | | Adjusted earnings per share | 1.11 | 0.95 | 0.16 | 16.8 % | | Cash flows provided by operating activities (In Millions) | 217.4 | 206.7 | 10.7 | 5.2 % | | Adjusted EBITDA (In Millions) | 271.8 | 249.6 | 22.2 | 8.9 % | | Adjusted free cash flow (In Millions) | 142.5 | 124.2 | 18.3 | 14.7 % | | Discharges | 60,833 | 57,011 | | 6.7 % | | Same-store discharge growth | | | | 4.8 % | | Net patient revenue per discharge | $20,803 | $20,387 | | 2.0 % | - Revenue growth of 9.6% resulted primarily from discharge growth of 6.7%, including same-store growth of 4.8%[4] - Cash flows provided by operating activities increased 5.2% to $217.4 million, primarily due to an increase in net income partly offset by higher cash tax payments[4] - Adjusted EBITDA increased 8.9%, primarily from increased revenue[4] CEO Commentary CEO Mark Tarr expressed satisfaction with Q2 performance, highlighting strong discharge growth, increased revenue and Adjusted EBITDA, capacity expansion, and resumed share repurchases, maintaining optimism for long-term prospects - Strong discharge growth facilitated an increase of 9.6% in revenue and 8.9% in Adjusted EBITDA[3] - During the quarter, 194 beds were added to capacity, and continued progress was made across key operating initiatives[3] - Activity under the share repurchase authorization was resumed, and the company remains highly-optimistic about long-term prospects[3] 2024 Financial Guidance Updated Full-Year 2024 Guidance Encompass Health increased its full-year 2024 guidance for net operating revenue, Adjusted EBITDA, and Adjusted earnings per share, reflecting confidence in continued performance Full-Year 2024 Guidance Comparison | Metric | Previous Guidance | Updated Guidance | | :------------------------------------------------------------------- | :---------------- | :--------------- | | Net operating revenue (In Millions) | $5,250 to $5,325 | $5,275 to $5,350 | | Adjusted EBITDA (In Millions) | $1,030 to $1,065 | $1,040 to $1,075 | | Adjusted earnings per share from continuing operations attributable to Encompass Health | $3.86 to $4.11 | $3.97 to $4.22 | - The Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share due to the inability to predict, with reasonable certainty, the future impact of items outside its control or not indicative of ongoing operating performance[5][10] - Reasonably estimable GAAP measures for 2024 include approximately $140 million for interest expense and amortization of debt discounts and fees, and approximately $10 million for amortization of debt-related items[11] Company Information About Encompass Health Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 164 hospitals across 38 states and Puerto Rico, providing high-quality rehabilitative care - Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States[7] - The company has a national footprint including 164 hospitals in 38 states and Puerto Rico[7] - It provides high-quality, compassionate rehabilitative care for patients recovering from major injury or illness, utilizing advanced technology and innovative treatments[7] Conference Call & Webcast The company will host an investor conference call on August 6, 2024, at 10:00 a.m. ET to discuss Q2 2024 results, with supplemental information available online - An investor conference call will be hosted on Tuesday, August 6, 2024, at 10:00 a.m. Eastern Time to discuss Q2 2024 results[6] - Supplemental information for the call will be posted on the company's website at http://investor.encompasshealth.com[6](index=6&type=chunk) Other Information & Non-GAAP Measures This section directs readers to SEC filings (10-Q, 8-K) for detailed information and provides context on the use and reconciliation of non-GAAP financial measures, explaining why GAAP guidance is not provided for certain metrics - This press release is summarized and should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and Current Report on Form 8-K filed on August 5, 2024[8] - The financial data includes non-GAAP financial measures such as adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow, with reconciliations to GAAP measures provided[9] - The Company does not provide GAAP guidance for certain measures due to the inability to predict, with reasonable certainty, the future impact of items deemed outside its control or not indicative of ongoing operating performance[10] Financial Statements (Unaudited) Condensed Consolidated Statements of Comprehensive Income The unaudited condensed consolidated statements of comprehensive income show a significant increase in net operating revenues and net income for both the three and six months ended June 30, 2024, compared to the prior year Condensed Consolidated Statements of Comprehensive Income | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :------------------------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net operating revenues (In Millions) | $1,301.2 | $1,187.1 | $2,617.2 | $2,347.5 | | Total operating expenses (In Millions) | 1,085.6 | 1,003.2 | 2,194.1 | 1,985.0 | | Income from continuing operations before income tax expense (In Millions) | 186.0 | 151.2 | 364.4 | 297.4 | | Net and comprehensive income attributable to Encompass Health (In Millions) | 114.1 | 91.4 | 226.6 | 179.1 | | Diluted earnings per share attributable to Encompass Health common shareholders: Continuing operations | $1.13 | $0.91 | $2.24 | $1.79 | Condensed Consolidated Balance Sheets The unaudited condensed consolidated balance sheets indicate an increase in total assets and shareholders' equity as of June 30, 2024, compared to December 31, 2023, with a notable rise in cash and cash equivalents Condensed Consolidated Balance Sheets | Metric | June 30, 2024 (In Millions) | December 31, 2023 (In Millions) | | :--------------------------------------------- | :-------------------------- | :------------------------------ | | Cash and cash equivalents | $154.4 | $69.1 | | Total current assets | 938.1 | 841.8 | | Property and equipment, net | 3,438.9 | 3,301.0 | | Total assets | $6,388.7 | $6,102.4 | | Total current liabilities | 694.5 | 656.4 | | Long-term debt, net of current portion | 2,684.1 | 2,687.8 | | Total liabilities | 3,858.7 | 3,805.2 | | Total shareholders' equity | 2,481.4 | 2,255.2 | Condensed Consolidated Statements of Cash Flows The unaudited condensed consolidated statements of cash flows show an increase in net cash provided by operating activities for the six months ended June 30, 2024, while investing activities primarily involved capital expenditures and financing activities included debt payments, dividends, and share repurchases Condensed Consolidated Statements of Cash Flows | Metric | Six Months Ended June 30, 2024 (In Millions) | Six Months Ended June 30, 2023 (In Millions) | | :-------------------------------------------------------- | :------------------------------------------- | :------------------------------------------- | | Net cash provided by operating activities | $456.2 | $434.6 | | Net cash used in investing activities | (288.1) | (232.5) | | Net cash used in financing activities | (90.2) | (101.5) | | Increase in cash, cash equivalents, and restricted cash | 77.9 | 100.6 | | Cash, cash equivalents, and restricted cash at end of period | $182.1 | $154.0 | Supplemental Financial Information Adjusted Earnings Per Share Reconciliations This section provides detailed reconciliations related to earnings per share, including the calculation of income from continuing operations attributable to Encompass Health and adjustments to arrive at adjusted EPS for various periods Income from Continuing Operations Attributable to Encompass Health This section provides a reconciliation of Adjusted EBITDA to Income from continuing operations attributable to Encompass Health, detailing adjustments for depreciation, interest, stock-based compensation, and other non-operating items for both three and six-month periods Income from Continuing Operations Attributable to Encompass Health Reconciliation | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :------------------------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Adjusted EBITDA (In Millions) | $271.8 | $249.6 | $544.8 | $478.6 | | Depreciation and amortization (In Millions) | (72.9) | (72.6) | (143.2) | (136.5) | | Interest expense and amortization of debt discounts and fees (In Millions) | (34.3) | (36.3) | (69.5) | (72.7) | | Stock-based compensation (In Millions) | (13.6) | (15.6) | (22.9) | (23.5) | | Income from continuing operations (In Millions) | $115.3 | $92.6 | $229.1 | $181.3 | | Diluted earnings per share | $1.13 | $0.91 | $2.24 | $1.79 | Adjusted Earnings Per Share Summary This table presents the reported and adjusted earnings per share, highlighting adjustments for asset impairment, income tax, state regulatory changes, and fair market value of equity securities Adjusted Earnings Per Share Summary | Metric | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 | | :----------------------------------------------- | :------ | :------ | :------------ | :------------ | | Earnings per share, as reported | $1.13 | $0.91 | $2.24 | $1.79 | | Adjustments, net of tax: | | | | | | Asset impairment impact | — | — | 0.02 | — | | Income tax adjustments | (0.02) | — | (0.03) | — | | State regulatory change impact | — | 0.03 | — | 0.03 | | Change in fair market value of equity securities | — | 0.01 | — | — | | Adjusted earnings per share | $1.11 | $0.95 | $2.23 | $1.83 | Detailed Adjusted EPS Reconciliations (Q2 2024, Q2 2023, 6 Months 2024, 6 Months 2023) These detailed tables reconcile diluted earnings per share from continuing operations to adjusted earnings per share for Q2 2024, Q2 2023, six months 2024, and six months 2023, showing specific adjustments for income tax, state regulatory changes, asset impairment, and fair market value of equity securities Q2 2024 Diluted EPS Reconciliation | Metric | As Reported | Income Tax Adjustments | Change in Fair Market Value of Equity Securities | As Adjusted | | :------------------------------------------------------------------- | :---------- | :--------------------- | :----------------------------------------------- | :---------- | | Income from continuing operations attributable to Encompass Health (In Millions) | $115.3 | $(2.4) | $0.3 | $113.2 | | Diluted earnings per share from continuing operations | $1.13 | $(0.02) | — | $1.11 | Q2 2023 Diluted EPS Reconciliation | Metric | As Reported | State Regulatory Change Impact | Income Tax Adjustments | Change in Fair Market Value of Equity Securities | As Adjusted | | :------------------------------------------------------------------- | :---------- | :----------------------------- | :--------------------- | :----------------------------------------------- | :---------- | | Income from continuing operations attributable to Encompass Health (In Millions) | $92.6 | $2.9 | $0.1 | $0.8 | $96.4 | | Diluted earnings per share from continuing operations | $0.91 | $0.03 | — | $0.01 | $0.95 | 6 Months 2024 Diluted EPS Reconciliation | Metric | As Reported | Asset Impairment Impact | Income Tax Adjustments | Change in Fair Market Value of Equity Securities | As Adjusted | | :------------------------------------------------------------------- | :---------- | :---------------------- | :--------------------- | :----------------------------------------------- | :---------- | | Income from continuing operations attributable to Encompass Health (In Millions) | $229.1 | $1.8 | $(3.0) | $0.1 | $228.0 | | Diluted earnings per share from continuing operations | $2.24 | $0.02 | $(0.03) | — | $2.23 | 6 Months 2023 Diluted EPS Reconciliation | Metric | As Reported | State Regulatory Change Impact | Income Tax Adjustments | Change in Fair Market Value of Equity Securities | As Adjusted | | :------------------------------------------------------------------- | :---------- | :----------------------------- | :--------------------- | :----------------------------------------------- | :---------- | | Income from continuing operations attributable to Encompass Health (In Millions) | $181.3 | $2.9 | $0.4 | $0.4 | $185.0 | | Diluted earnings per share from continuing operations | $1.79 | $0.03 | — | — | $1.83 | Adjusted EBITDA Reconciliations This section provides reconciliations for Adjusted EBITDA, detailing adjustments from both net cash provided by operating activities and net income for various periods Net Cash Provided by Operating Activities to Adjusted EBITDA This reconciliation details the adjustments from net cash provided by operating activities to Adjusted EBITDA, including interest expense, equity in nonconsolidated affiliates, tax expenses, and changes in assets/liabilities Net Cash Provided by Operating Activities to Adjusted EBITDA Reconciliation | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :------------------------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net cash provided by operating activities (In Millions) | $217.4 | $206.7 | $456.2 | $434.6 | | Interest expense and amortization of debt discounts and fees (In Millions) | 34.3 | 36.3 | 69.5 | 72.7 | | Equity in net income of nonconsolidated affiliates (In Millions) | 1.4 | 0.9 | 2.1 | 1.3 | | Current portion of income tax expense (In Millions) | 40.6 | 36.5 | 72.4 | 64.4 | | Change in assets and liabilities (In Millions) | 11.8 | (3.5) | 13.4 | (41.4) | | Adjusted EBITDA (In Millions) | $271.8 | $249.6 | $544.8 | $478.6 | Net Income to Adjusted EBITDA This reconciliation shows the adjustments from net income to Adjusted EBITDA, accounting for discontinued operations, noncontrolling interests, income tax, interest, depreciation, and other non-operating items Net Income to Adjusted EBITDA Reconciliation | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :------------------------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net income (In Millions) | $146.5 | $117.2 | $285.3 | $230.5 | | Loss from discontinued operations, net of tax, attributable to Encompass Health (In Millions) | 1.2 | 1.2 | 2.5 | 2.2 | | Provision for income tax expense (In Millions) | 38.3 | 32.8 | 76.6 | 64.7 | | Interest expense and amortization of debt discounts and fees (In Millions) | 34.3 | 36.3 | 69.5 | 72.7 | | Depreciation and amortization (In Millions) | 72.9 | 72.6 | 143.2 | 136.5 | | Adjusted EBITDA (In Millions) | $271.8 | $249.6 | $544.8 | $478.6 | Adjusted Free Cash Flow Reconciliation This section reconciles net cash provided by operating activities to adjusted free cash flow, factoring in capital expenditures for maintenance, distributions to noncontrolling interests, and transaction costs Adjusted Free Cash Flow Reconciliation | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :------------------------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net cash provided by operating activities (In Millions) | $217.4 | $206.7 | $456.2 | $434.6 | | Impact of discontinued operations (In Millions) | 2.0 | 1.6 | 2.7 | 2.9 | | Capital expenditures for maintenance (In Millions) | (48.9) | (56.7) | (87.6) | (94.5) | | Distributions paid to noncontrolling interests of consolidated affiliates (In Millions) | (27.8) | (27.6) | (52.5) | (59.4) | | Transaction costs and related liabilities (In Millions) | (0.2) | 0.2 | (8.7) | (0.7) | | Adjusted free cash flow (In Millions) | $142.5 | $124.2 | $310.1 | $282.9 | Investing and Financing Activities Summary This section provides a narrative summary of cash flows from investing and financing activities for the three and six months ended June 30, 2024 and 2023, highlighting capital expenditures, debt payments, dividends, and share repurchases - For the three months ended June 30, 2024, net cash used in investing activities was $158.4 million, primarily from capital expenditures[34] - Net cash used in financing activities during the three months ended June 30, 2024, was $49.6 million, primarily from distributions paid to noncontrolling interests, cash dividends paid on common stock, and repurchases of common stock, partially offset by contributions from noncontrolling interests[34] - For the six months ended June 30, 2024, net cash used in investing activities was $288.1 million, primarily from capital expenditures[35] - Net cash used in financing activities during the six months ended June 30, 2024, was $90.2 million, primarily from distributions paid to noncontrolling interests, cash dividends paid on common stock, and repurchases of common stock, partially offset by contributions from noncontrolling interests[35] Forward-Looking Statements Disclaimer and Risk Factors This section serves as a comprehensive disclaimer, outlining that statements regarding future business, strategy, financial guidance, and other projections are forward-looking and subject to various risks and uncertainties that could cause actual results to differ materially - Statements regarding business, strategy, outlook, growth targets, guidance, dividend strategies, and financial plans are forward-looking statements[38] - All estimates, projections, and forward-looking information are based on current information, and Encompass Health undertakes no duty to publicly update or revise such information[38] - Actual events or results may differ materially due to a variety of factors, including infectious disease outbreaks, demand for services, legal proceedings, ability to attract and retain key personnel, information system disruptions, integration of acquisitions, changes in reimbursement, competitive pressures, labor costs, and general economic conditions[38][39]